Efavirenz; lamivudine; tenofovir disoproxil fumarate - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for efavirenz; lamivudine; tenofovir disoproxil fumarate and what is the scope of freedom to operate?
Efavirenz; lamivudine; tenofovir disoproxil fumarate
is the generic ingredient in three branded drugs marketed by Aurobindo Pharma Ltd, Laurus, Macleods Pharms Ltd, Mylan Labs Ltd, and Mylan, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.Two suppliers are listed for this compound.
Summary for efavirenz; lamivudine; tenofovir disoproxil fumarate
| US Patents: | 0 |
| Tradenames: | 3 |
| Applicants: | 5 |
| NDAs: | 6 |
| Finished Product Suppliers / Packagers: | 2 |
| Clinical Trials: | 28 |
| DailyMed Link: | efavirenz; lamivudine; tenofovir disoproxil fumarate at DailyMed |
Recent Clinical Trials for efavirenz; lamivudine; tenofovir disoproxil fumarate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida | N/A |
| Professor Francois Venter | Phase 3 |
| Yu-Jay Corp. | Phase 3 |
See all efavirenz; lamivudine; tenofovir disoproxil fumarate clinical trials
Pharmacology for efavirenz; lamivudine; tenofovir disoproxil fumarate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | SYMFI LO | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 208255-001 | Feb 5, 2018 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Laurus | EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 213038-001 | May 14, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Laurus | EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE | efavirenz; lamivudine; tenofovir disoproxil fumarate | TABLET;ORAL | 212786-001 | May 14, 2020 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
